Renal Cancer - Results from #1140

Proteomics Characterization of Clear Cell Renal Cell Carcinoma. January 10, 2023

Patient Factors Impacting Perioperative Outcomes for T1b-T2 Localized Renal Cell Carcinoma May Guide Decision for Partial versus Radical Nephrectomy. January 10, 2023

Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups. January 9, 2023

Percutaneous cryoablation versus partial nephrectomy for cT1b renal tumors: An inverse probability weight analysis. January 9, 2023

Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. January 6, 2023

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. January 6, 2023

The State of Robotic Partial Nephrectomy: Operative, Functional, and Oncological Outcomes from A Robust Multi-Institution Collaborative. January 5, 2023

Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma. January 5, 2023

Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors. January 4, 2023

Association of Volatile Versus Intravenous Anesthesia With Prognosis After Nephrectomy for Renal Cell Carcinoma. January 4, 2023

Age-Related Differences in Oncological Outcomes in Renal Cell Carcinoma: Impact of Functional Conservation as Measured by Postoperative eGFR. January 3, 2023

Semantic computed tomography features for predicting BRCA1-associated protein 1 and/or tumor protein p53 gene mutation status in clear cell renal cell carcinoma. January 3, 2023

Nomograms for predicting overall and cancer-specific survival of patients with chromophobe renal cell carcinoma after nephrectomy: a retrospective SEER-based study. January 2, 2023

No difference in renal function outcomes for patients with oncocytoma managed with active surveillance vs. partial nephrectomy. January 2, 2023

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. December 30, 2022

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. December 30, 2022

Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. December 29, 2022

Characterization of Patients with Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-Line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). December 29, 2022

Perioperative outcomes following robot-assisted partial nephrectomy for complex renal masses: A Vattikuti Collective Quality Initiative database study. December 28, 2022

Meta-Analysis on Long-Term Outcomes of Pediatric Renal Cancer Survivors Following COG and SIOP Protocols. December 28, 2022

Page 58 of 456